ShockWave Medical (NASDAQ:SWAV) Shares Down 4.5%
ShockWave Medical (NASDAQ:SWAV) Shares Down 4.5%
ShockWave Medical, Inc. (NASDAQ:SWAV – Get Rating)'s share price fell 4.5% on Wednesday . The company traded as low as $188.38 and last traded at $189.40. 169,059 shares traded hands during mid-day trading, a decline of 67% from the average session volume of 506,107 shares. The stock had previously closed at $198.34.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on SWAV. Deutsche Bank Aktiengesellschaft assumed coverage on ShockWave Medical in a research note on Friday, December 16th. They set a "buy" rating and a $285.00 target price on the stock. Canaccord Genuity Group lifted their target price on ShockWave Medical from $247.00 to $252.00 and gave the stock a "buy" rating in a research report on Friday, February 17th. Piper Sandler cut their price target on shares of ShockWave Medical from $300.00 to $280.00 and set an "overweight" rating on the stock in a report on Thursday, January 26th. Morgan Stanley decreased their price objective on shares of ShockWave Medical from $290.00 to $224.00 and set an "equal weight" rating for the company in a report on Friday, January 6th. Finally, Wells Fargo & Company upped their target price on shares of ShockWave Medical from $200.00 to $207.00 and gave the stock an "equal weight" rating in a research note on Friday, February 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $248.22.
Get ShockWave Medical alerts:ShockWave Medical Stock Down 2.9 %
The business has a 50 day moving average of $192.26 and a two-hundred day moving average of $239.36. The stock has a market capitalization of $7.03 billion, a PE ratio of 34.80 and a beta of 0.97. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.06 and a current ratio of 7.25.
ShockWave Medical (NASDAQ:SWAV – Get Rating) last released its quarterly earnings results on Thursday, February 16th. The company reported $3.71 EPS for the quarter, beating the consensus estimate of $0.99 by $2.72. The business had revenue of $144.00 million during the quarter, compared to analyst estimates of $143.04 million. ShockWave Medical had a net margin of 44.10% and a return on equity of 59.99%. The company's quarterly revenue was up 71.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.34 earnings per share. Analysts predict that ShockWave Medical, Inc. will post 3.91 EPS for the current year.
Insiders Place Their Bets
In other news, insider Isaac Zacharias sold 4,000 shares of the firm's stock in a transaction on Monday, February 27th. The stock was sold at an average price of $188.51, for a total value of $754,040.00. Following the completion of the sale, the insider now owns 64,619 shares of the company's stock, valued at approximately $12,181,327.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Isaac Zacharias sold 4,000 shares of the stock in a transaction that occurred on Monday, February 27th. The shares were sold at an average price of $188.51, for a total value of $754,040.00. Following the completion of the transaction, the insider now directly owns 64,619 shares of the company's stock, valued at approximately $12,181,327.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Dan Puckett sold 1,100 shares of ShockWave Medical stock in a transaction that occurred on Tuesday, December 20th. The stock was sold at an average price of $212.93, for a total transaction of $234,223.00. Following the completion of the sale, the chief financial officer now owns 39,938 shares of the company's stock, valued at $8,503,998.34. The disclosure for this sale can be found here. Over the last three months, insiders have sold 65,678 shares of company stock valued at $12,616,643. 3.90% of the stock is currently owned by insiders.
Hedge Funds Weigh In On ShockWave Medical
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SWAV. Raymond James & Associates raised its stake in shares of ShockWave Medical by 1.8% in the first quarter. Raymond James & Associates now owns 4,644 shares of the company's stock worth $963,000 after purchasing an additional 81 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in ShockWave Medical by 2.6% during the 1st quarter. Bank of New York Mellon Corp now owns 151,238 shares of the company's stock valued at $31,361,000 after acquiring an additional 3,771 shares during the period. Rhumbline Advisers boosted its holdings in shares of ShockWave Medical by 1.5% in the 1st quarter. Rhumbline Advisers now owns 35,441 shares of the company's stock valued at $7,349,000 after acquiring an additional 526 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in shares of ShockWave Medical during the first quarter worth $407,000. Finally, Canada Pension Plan Investment Board lifted its position in ShockWave Medical by 36.3% during the first quarter. Canada Pension Plan Investment Board now owns 800 shares of the company's stock valued at $166,000 after purchasing an additional 213 shares during the period. Hedge funds and other institutional investors own 90.56% of the company's stock.
ShockWave Medical Company Profile
(Get Rating)
Shockwave Medical, Inc operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease.
Featured Articles
- Get a free copy of the StockNews.com research report on ShockWave Medical (SWAV)
- Should You Park Some Capital with Casey's General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
- Occidental Petroleum: What Would Warren Buffett Do?
- Is Unity Software Earnings Fallout a Buying Opportunity?
- Why Wall Street Is Still So Constructive on Aecom Stock
Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.
衝擊波醫療公司股價週三下跌4.5%。該公司股價最低跌至188.38美元,最新報189.40美元。午盤,169,059股股票易手,較506,107股的平均成交量下跌67%。該股此前收盤報198.34美元。
華爾街分析師預測經濟增長
一些研究公司最近對SWAV發表了評論。德意志銀行Aktiengesellschaft在12月16日星期五的一份研究報告中對Shockwave Medical進行了報道。他們為該股設定了“買入”評級和285.00美元的目標價。Cancord Genuity Group將Shockwave Medical的目標價從247.00美元上調至252.00美元,並在2月17日星期五的一份研究報告中給予該股“買入”評級。派珀·桑德勒在1月26日週四的一份報告中將Shockwave Medical的目標價從300.00美元下調至280.00美元,並將該股的評級定為“增持”。摩根士丹利在上週五的一份報告中將衝擊波醫療的目標股價從290.00美元下調至224.00美元,並對該公司設定了“同等權重”的評級。最後,富國銀行將Shockwave Medical的目標股價從200.00美元上調至207.00美元,並在2月17日星期五的一份研究報告中給予該股“同等權重”的評級。一名股票研究分析師將該股評級為賣出,兩名分析師給出了持有評級,五名分析師給出了該公司股票的買入評級。根據MarketBeat.com的數據,該股目前的平均評級為“中等買入”,平均目標價為248.22美元。
到達衝擊波醫療警報:衝擊波醫療類股下跌2.9%
該業務的50日移動均線切入位在192.26美元,200日移動均線切入位在239.36美元。該股市值70.3億美元,本益比34.80倍,貝塔係數0.97。該公司的負債權益比率為0.05,速動比率為6.06,流動比率為7.25。
衝擊波醫療(納斯達克:SWAV-GET評級)最近一次發佈季度收益報告是在2月16日(星期四)。該公司公佈本季度每股收益為3.71美元,比普遍預期的0.99美元高出2.72美元。該業務本季度營收為1.44億美元,而分析師預期為1.4304億美元。Shockwave Medical的淨利潤率為44.10%,股本回報率為59.99%。該公司季度營收同比增長71.0%。去年同期,該公司公佈的每股收益為0.34美元。分析師預測,Shockwave Medical,Inc.本年度每股收益將達到3.91美元。
內部人士下注
在其他新聞中,內部人士Isaac Zacharias在2月27日星期一的一次交易中出售了4000股該公司的股票。這只股票的平均售價為188.51美元,總價值為754,040.00美元。出售完成後,這位內部人士現在擁有該公司64,619股股票,價值約12,181,327.69美元。這筆交易是在提交給美國證券交易委員會的一份法律檔案中披露的,該檔案可以通過美國證券交易委員會網站。在相關新聞中,內部人士Isaac Zacharias在2月27日星期一的一筆交易中出售了4000股該股。這些股票的平均價格為188.51美元,總價值為754,040.00美元。交易完成後,這位內部人士現在直接擁有該公司64,619股股票,價值約12,181,327.69美元。這筆交易是在提交給美國證券交易委員會的一份法律檔案中披露的,該檔案可通過美國證券交易委員會網站。此外,首席財務官丹·帕克特在12月20日(星期二)的一筆交易中出售了1100股Shockwave Medical的股票。該股以212.93美元的平均價格出售,總成交金額為234,223.00美元。出售完成後,首席財務官現在擁有該公司39,938股股票,價值8,503,998.34美元。關於這次銷售的披露可以找到這裡。在過去的三個月裡,內部人士已經出售了65,678股公司股票,價值12,616,643美元。該公司3.90%的股份目前由內部人士持有。
對沖基金參與ShockWave Medical
一些對沖基金和其他機構投資者最近增持或減持了SWAV的股份。Raymond James&Associates在第一季度將其在Shockwave Medical的股票持股增加了1.8%。Raymond James&Associates在上個季度又購買了81股,現在擁有4644股該公司股票,價值96.3萬美元。紐約梅隆銀行(Bank Of New York Mellon Corp)在第一季度增持ShockWave Medical的股份2.6%。紐約梅隆銀行(Bank Of New York Mellon Corp)目前持有151,238股該公司股票,價值31,361,000美元,在此期間又購買了3,771股。Rhumbline Advisers在第一季度將Shockwave Medical的股票持有量增加了1.5%。Rhumbline Advisers在上個季度增持了526股後,現在擁有該公司35,441股股票,價值7,349,000美元。馮託貝爾控股有限公司在第一季度購買了價值407,000美元的Shockwave Medical的新頭寸。最後,加拿大養老金計劃投資委員會在第一季度將其在Shockwave Medical的頭寸提高了36.3%。加拿大養老金計劃投資委員會在此期間又購買了213股,現在擁有800股該公司的股票,價值16.6萬美元。對沖基金和其他機構投資者持有該公司90.56%的股票。
衝擊波醫療公司簡介
(獲取評級)
ShockWave Medical,Inc.是一家醫療設備公司,專注於開發旨在改變鈣化心血管疾病治療方式的產品並將其商業化。該公司提供用於治療膝蓋以上週圍動脈疾病的M5導管,用於治療冠狀動脈疾病的C2導管,以及用於治療膝蓋以下週圍動脈疾病的S4導管。
專題文章
- 免費獲取StockNews.com關於Shockwave Medical(SWAV)的研究報告
- 你應該在凱西的百貨商店裡預留一些資本嗎?
- CrowdStrike股票:趁熱打鐵!
- 西方石油:沃倫·巴菲特會怎麼做?
- Unity Software的收入暴跌是買入機會嗎?
- 為什麼華爾街仍然對Aecom股票如此有建設性
接受《衝擊波醫學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對ShockWave Medical和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧